

Docket No. 215246US0PCT

O I P E
AUG 07 2003
PATENT & TRADEMARK OFFICE
JC34

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ryuji UENO

SERIAL NO: 09/926,411

GAU: 1615

FILED: October 29, 2001

EXAMINER: AZPURU

FOR: USE OF MACROLIDE COMPOUNDS FOR THE TREATMENT OF DRY EYE

RECEIVED
TECH CENTER 1600/2900
AUG 11 2003

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment form is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

08/06/2003 0000036 00000000

01 FEE:1806

180.00 1P

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon
Registration No. 24,618



22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Stephen G. Baxter, Ph.D.
Registration No. 32,884

RECEIVED
AUG 11 2003
VINCENT K. SHIER, PH.D.
REGISTRATION NUMBER 50,552



Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 215246US0PCT	SERIAL NO. 09/926,411	
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Ryuji UENO				
		FILING DATE October 29, 2001		GROUP 1615		
U.S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS
	AA	5,457,182	10/10/95	WIEDERRECHT, et al.		
	AB	5,770,607	6/23/98	HONBO, et al.		
	AC	5,952,371	9/14/99	BAKER, et al.		
	AD	6,004,565	12/21/99	CHIBA, et al.		
FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO	
	AE	EP 0 184 162 A2	6/11/86	European		
	AF	EP 0 240 773 A1	10/14/87	European		
	AG	WO 89/05303	6/15/89	WIPO		
	AH	EP 0 323 042 A1	7/5/89	European		
	AI	EP 0 406 791 A2	1/9/91	European		
	AJ	EP 0 423 714 A2	4/24/91	European		
	AK	EP 0 427 680 A1	5/15/91	European		
	AL	WO 91/13889	9/19/91	WIPO		
	AM	WO 91/19495	12/26/91	WIPO		
	AN	EP 0 465 426 A1	1/8/92	European		
	AO	EP 0 480 623 A1	4/15/92	European		
	AP	EP 0 532 088 A1	3/17/93	European		
	AQ	EP 0 532 089 A1	3/17/93	European		
	AR	WO 93/05058	3/18/93	WIPO		
	AS	WO 93/05059	3/18/93	WIPO		
	AT	EP 0 569 337 A1	11/10/93	European		
	AU	WO 94/09010	4/28/94	WIPO		
	AV	EP 0 626 385 A1	11/30/94	European		
	AW	WO 95/16691	6/22/95	WIPO		
	AX	WO 96/31514	10/10/96	WIPO		
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)						
	AY	YAMADA, M., et al., <u>Folia Ophthalmol. Jpn.</u> , vol. 43, pp. 1289-1293 (1992).				
	AZ					
					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered	

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.